Meyka Pro banner
Nuvectis Pharma, Inc.

Nuvectis Pharma, Inc. (NVCT) Stock Overview

Explore Nuvectis Pharma, Inc.’s financial performance, market position, analyst ratings, and future outlook.

NVCTNASDAQ
HealthcareBiotechnology
$19.29
$1.26(6.99%)
U.S. Market opens in 1h 34m

Nuvectis Pharma, Inc. (NVCT)

Meyka AI Score

Z

Key Financials

Market Cap506.3M
P/E Ratio-14.84
EPS (TTM)$-1.31
ROE-1.48%
Fundamental Analysis

AI Price Forecasts

1 Month$16.45
3 Months$10.89
1 Year Target$8.36

NVCT Stock Analysis & Investment Overview

Our comprehensive AI-powered analysis of Nuvectis Pharma, Inc. (NVCT) provides investors with deep insights into the stock's performance, growth potential, and market positioning. With a Meyka AI Score of B, this stock demonstrates moderate investment characteristics based on our advanced machine learning models.

The current technical analysis reveals key indicators including an RSI of 55.21, suggesting the stock is in a neutral condition. Our forecasting models predict significant price movements, with a 12-month target of $8.36.

Key financial metrics showcase the company's fundamental strength, including a P/E ratio of -14.84 and a market capitalization of 506.3M. These metrics, combined with our AI analysis, provide a comprehensive view for both institutional and retail investors.

1-Day Change
1.10%
5-Day Change
5.41%
1-Month Change
16.70%
3-Month Change
118.71%
6-Month Change
120.21%
Year-to-Date (YTD) Change
155.50%
1-Year Change
138.74%
3-Year Change
32.58%
5-Year Change
493.54%
All-Time (Max) Change
493.54%

Contact Information

201 614 3150
1 Bridge Plaza, Fort Lee, NJ, 07024

Company Facts

130 Employees
IPO DateFeb 4, 2022
CountryUS
Actively Trading

Frequently Asked Questions